We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Identification Method for Cancerous DNA to Reduce Need for Painful Biopsy Surgery

By LabMedica International staff writers
Posted on 09 Sep 2024
Image: Microfluidic testing in the lab (Photo courtesy of Heriot-Watt University)
Image: Microfluidic testing in the lab (Photo courtesy of Heriot-Watt University)

Currently, most cancer patients must undergo an invasive and expensive surgical biopsy to remove a tissue sample from their tumor to determine the best treatment options. However, all individuals have small amounts of DNA that circulate freely in their blood, which is not confined within blood cells. In cancer patients, some of this circulating free DNA (ctDNA) originates from their tumors. This ctDNA differs from their normal circulating DNA as it carries mutations that have turned these cells from healthy to cancerous. Thus, ctDNA can provide insights into the cancer's characteristics and indicate which treatments might be most effective. Existing methods to analyze ctDNA are hampered by its low abundance and the presence of a larger quantity of non-cancerous DNA in the blood samples.

Researchers at Heriot-Watt University (Edinburgh, UK) are now developing a novel method to identify cancerous DNA that could reduce the need for painful biopsies. This new technique, known as SNARE, aims to simplify the processing of blood samples to enhance the detection and characterization of cancerous DNA. The team is working on creating both robotic benchtop systems and microfluidic platforms (similar to certain types of lateral flow tests) and will evaluate these methods using blood samples from breast cancer patients to achieve more sensitive ctDNA detection and reduce the need for expensive DNA sequencing.

In patients with advanced-stage cancer, significant amounts of DNA in the bloodstream can often be detected, but by this stage, it is frequently too late for a cure. On the other hand, in early-stage cancer patients, where treatment success rates are higher, over 99% of the circulating free DNA typically originates from healthy cells, complicating the identification of cancerous mutations. The Heriot-Watt research team plans to further develop MicroSNARE, which they have already tested in the lab, with the aim of diagnosing, analyzing, and characterizing tumors at an earlier stage. They also aim to detect cancer recurrence before it can progress and spread. MicroSNARE promises a groundbreaking, less invasive approach to cancer detection, potentially enabling earlier diagnosis and intervention.

Related Links:
Heriot-Watt University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA

Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Blood Biomarker May Track Bone Metastases in Medullary Thyroid Cancer

Medullary thyroid cancer (MTC) is a rare malignancy that often progresses silently, frequently going undetected until it reaches advanced stages. By the time it spreads to bone, it can produce unusual... Read more

Molecular Diagnostics

view channel
Image: In the Fetal Extracellular Vesicle Monitoring of Oxygenation (FEMOx) project several of the Wyss Institute’s Technology Platforms and faculty labs join forces. Leveraging and integrating multiple of the Wyss Institute’s technological innovations and advanced analytical capabilities they aim develop a test that can rapidly and accurately detect fetal oxygen deprivation by detecting specific miRNA signatures in extracellular vesicles (EVs) that circulate in maternal blood. (Iimage Credit: Wyss Institute at Harvard University)

Project to Develop Maternal Blood Test for Rapid Fetal Oxygen Deprivation Detection

Intrapartum fetal hypoxia remains difficult to assess with existing monitoring, leaving clinicians to make time-critical decisions with incomplete data. Limited detection and interpretation can contribute... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more